Status:
COMPLETED
Evaluation of ACCS100 to Reduce Aflatoxin Exposure in Kenya
Lead Sponsor:
Kenya Medical Research Institute
Collaborating Sponsors:
Centers for Disease Control and Prevention
Texas A&M University
Conditions:
Aflatoxicosis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to pilot test the effectiveness, acceptability, and palatability of ACCS100 in a high-risk Kenyan population.
Detailed Description
Aflatoxins are harmful by-products of the molds Aspergillus flavus and A. parasiticus and are major contaminants of agricultural produce such as maize. Acute aflatoxin exposure (i.e., aflatoxicosis) c...
Eligibility Criteria
Inclusion
- Adult ≥18 years of age
- Consumes corn- and/or peanut-derived foods at least four times per week
- No plans to travel away from the household for more than one day in the next month
Exclusion
- Women who may be pregnant
- History of medical illnesses
- Presence of protein or glucose in urine using chemstrip
- Does not provide informed consent
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT02188953
Start Date
August 1 2014
End Date
September 1 2014
Last Update
September 16 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Makindu Health Center
Makindu, Kenya